DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
— - 2 Hakyung Kim - 2 Jesse Pound - 2 Bob Duggan - 1 Maky - 1 Dell - 1 Merck's - 1 Andrew Didora - 1
Top related locs:
Florida Davos Switzerland
Top related orgs:
Summit Therapeutics - 2 Dell Technologies - 2 American Airlines - 2 Etsy - 2 JetBlue Airways — - 2 Bank of America - 2 JetBlue - 2 Citi - 2

Search resuls for: "Summit Therapeutics"


4 mentions found


☆ Summit Therapeutics Co-CEOs on what's next for lung cancer drug
  + stars: | 2024-09-11 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSummit Therapeutics Co-CEOs on what's next for lung cancer drugBob Duggan & Maky Zanganeh, Summit Therapeutics co-CEOs, join 'Fast Money' to talk its lung cancer drug and continuing treatment studies.
Persons: Bob Duggan, Maky Organizations: Summit Therapeutics Co, Summit Therapeutics
☆ Stocks making the biggest moves midday: Palantir Technologies, Summit Therapeutics, JetBlue Airways and more
  + stars: | 2024-09-09 | by ( Sean Conlon | ) www.cnbc.com   time to read: +2 min
Check out the companies making headlines in midday trading: Palantir Technologies , Dell Technologies — Palantir and Dell jumped 14% and nearly 4%, respectively, following the announcement after the bell Friday that both stocks would join the S & P 500 before the open on Sept. 23. Palantir is set to take American Airlines' spot, while Dell is going to replace Etsy. JetBlue Airways — The airline stock popped around 7% after Bank of America analyst Andrew Didora upgraded the firm to neutral from underperform. Cannabis stocks — Cannabis stocks moved higher after former President Donald Trump said in a Truth Social post that he will support legalizing adult marijuana use in Florida. A logo outside the Palantir Technologies pavilion ahead of the World Economic Forum in Davos, Switzerland, on Jan. 15, 2024.
Persons: Dell, Merck's, Andrew Didora, Didora, Arm's, Donald Trump, —, Alex Harring, Hakyung Kim, Yun Li, Jesse Pound, Michelle Fox, Stefan Wermuth Organizations: Palantir Technologies, Dell Technologies, American Airlines, Etsy, Therapeutics, Merck, JetBlue Airways —, Bank of America, JetBlue, Boeing, Citi, Federal Reserve, Arm Holdings, Financial, Apple, Monday, United States Steel, JPMorgan, Nippon Steel, Tilray Brands, Cannabis ETF, Economic, Bloomberg, Getty Locations: Florida, Davos, Switzerland
☆ Stocks making the biggest premarket moves: Boeing, Dell, Merck and more
  + stars: | 2024-09-09 | by ( Michelle Fox | ) www.cnbc.com   time to read: +2 min
MarineMax — Shares jumped 6% after Citi upgraded shares to buy from neutral. Palantir Technologies , Dell Technologies — Shares of Palantir and Dell rallied 8% and 5%, respectively, after it was announced postmarket Friday that the stocks would join the S & P 500 index. Palantir will replace American Airlines , while Dell will replace Etsy . Summit shares soared more than 30%. United States Steel — Shares moved about 3% higher after JPMorgan upgraded the industrial stock to overweight from neutral.
Persons: Merck, Summit, —, Jesse Pound, Hakyung Kim, Sarah Min, Sean Conlon Organizations: Boeing —, Citi, Technologies, Dell Technologies, Dell, American Airlines, Etsy, Summit Therapeutics, Summit, Arm Holdings, Times, Apple, United States Steel, JPMorgan, Nippon Steel, JetBlue Airways —, Bank of America, JetBlue
☆ Summit Therapeutics in up to $5 bln licensing deal for Akeso's cancer therapy
  + stars: | 2022-12-06 | by ( ) www.reuters.com   time to read: +1 min
Dec 6 (Reuters) - Summit Therapeutics Inc (SMMT.O) said on Tuesday it would license China-based Akeso Inc's (9926.HK) experimental cancer therapy in a deal worth up to $5 billion, sending its shares up 57% in premarket trade. The deal involves an upfront payment of $500 million to Akeso, which will also be eligible for regulatory and commercial milestone payments of up to $4.5 billion. Additionally, Akeso will be eligible to receive low double-digit royalties on net sales, Summit said in a statement. Through the deal, Summit will get the rights to develop and commercialize the drug, ivonescimab, in the United States, Canada, Europe, and Japan, while Akeso will retain the rights for rest of the world, including China. The company also announced a $500 million rights offering and the issuance of $520 million in promissory notes.
0 next >>
Total: 4